Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：16 / 16
页数：1
相关论文
共 50 条
  • [1] Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)
    Broeckelmann, Paul J.
    Goergen, Helen
    Keller, Ulrich
    Meissner, Julia
    Ordemann, Rainer
    Halbsguth, Teresa V.
    Sasse, Stephanie
    Soekler, Martin
    Kerkhoff, Andrea
    Mathas, Stephan
    Huttmann, Andreas
    Bormann, Matthias
    Zimmermann, Andreas
    Fuchs, Michael
    von Tresckow, Bastian
    Baues, Christian
    Rosenwald, Andreas
    Klapper, Wolfram
    Kobe, Carsten
    Borchmann, Peter
    Engert, Andreas
    [J]. BLOOD, 2019, 134
  • [2] Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
    Broeckelmann, Paul J.
    Goergen, Helen
    Keller, Ulrich
    Meissner, Julia
    Ordemann, Rainer
    Halbsguth, Teresa V.
    Sasse, Stephanie
    Soekler, Martin
    Kerkhoff, Andrea
    Mathas, Stephan
    Huettmann, Andreas
    Bormann, Matthias
    Zimmermann, Andreas
    Mettler, Jasmin
    Fuchs, Michael
    von Tresckow, Bastian
    Baues, Christian
    Rosenwald, Andreas
    Klapper, Wolfram
    Kobe, Carsten
    Borchmann, Peter
    Engert, Andreas
    [J]. JAMA ONCOLOGY, 2020, 6 (06) : 872 - 880
  • [3] Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Meissner, Julia
    Trautmann-Grill, Karolin
    Herhaus, Peter
    Halbsguth, Teresa, V
    Schaub, Valdete
    Kerkhoff, Andrea
    Mathas, Stephan
    Bormann, Matthias
    Dickhut, Andreas
    Kaul, Helen
    Fuchs, Michael
    Kobe, Carsten
    Baues, Christian
    Borchmann, Peter
    Engert, Andreas
    von Tresckow, Bastian
    [J]. BLOOD, 2022, 140 : 1753 - 1755
  • [4] Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial
    Brockelmann, Paul J.
    Goergen, Helen
    Keller, Ulrich
    Meissner, Julia
    Trautmann, Karolin
    Halbsguth, Teresa V.
    Sasse, Stephanie
    Sokler, Martin
    Kerkhoff, Andrea
    Mathas, Stephan
    Huttmann, Andreas
    Bormann, Matthias
    Zimmermann, Andreas
    Fuchs, Michael
    von Tresckow, Bastian
    Baues, Christian
    Rosenwald, Andreas
    Klapper, Wolfram
    Kobe, Carsten
    Borchmann, Peter
    Engert, Andreas
    [J]. BLOOD, 2020, 136
  • [5] Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial
    Voltin, Conrad-Amadeus
    Mettler, Jasmin
    Mueller, Horst
    Fuchs, Michael
    Baues, Christian
    Dietlein, Markus
    Engert, Andreas
    Borchmann, Peter
    Kobe, Carsten
    Brockelmann, Paul J.
    [J]. BLOOD, 2019, 134
  • [6] Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Meissner, Julia
    Trautmann-Grill, Karolin
    Herhaus, Peter
    Halbsguth, Teresa V.
    Schaub, Valdete
    Kerkhoff, Andrea
    Mathas, Stephan
    Bormann, Matthias
    Dickhut, Andreas
    Kaul, Helen
    Fuchs, Michael
    Kobe, Carsten
    Baues, Christian
    Borchmann, Peter
    Engert, Andreas
    von Tresckow, Bastian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1193 - +
  • [7] Brentuximab Vedotin and AVD Chemotherapy Followed by ISRT: A Safe Primary Treatment Regimen for Early-Stage, Unfavorable Hodgkin Lymphoma
    Yang, J. C.
    Kumar, A.
    Chapman, K. L.
    Constine, L. S.
    Moskowitz, C. H.
    Yahalom, J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S21 - S21
  • [8] Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
    Allen, Pamela B.
    Savas, Hatice
    Evens, Andrew M.
    Advani, Ranjana H.
    Palmer, Brett
    Pro, Barbara
    Karmali, Reem
    Mou, Eric
    Bearden, Jeffrey
    Dillehay, Gary
    Bayer, Robert A.
    Eisner, Robert M.
    Chmiel, Joan S.
    O'Shea, Kaitlyn
    Gordon, Leo I.
    Winter, Jane N.
    [J]. BLOOD, 2021, 137 (10) : 1318 - 1326
  • [9] EARLY UNFAVORABLE CLASSIC HODGKIN LYMPHOMA TREATED WITH A plus AVD IN A PEDIATRIC PATIENT
    Odetola, Olayinka
    McCall, David
    Gibson, Amber
    Nunez, Cesar
    Cuglievan, Branko
    Garcia, Miriam
    Roth, Micheal
    [J]. PEDIATRIC BLOOD & CANCER, 2023, 70 : S78 - S79
  • [10] Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Kumar, Anita
    Casulo, Carla
    Yahalom, Joachim
    Schoder, Heiko
    Barr, Paul M.
    Caron, Philip
    Chiu, April
    Constine, Louis S.
    Drullinsky, Pamela
    Friedberg, Jonathan W.
    Gerecitano, John F.
    Hamilton, Audrey
    Hamlin, Paul A.
    Horwitz, Steven M.
    Jacob, Alexandra G.
    Matasar, Matthew J.
    McArthur, Gianna N.
    McCall, Susan J.
    Moskowitz, Alison J.
    Noy, Ariela
    Palomba, Maria L.
    Portlock, Carol S.
    Straus, David J.
    VanderEls, Nicholas
    Verwys, Stephanie L.
    Yang, Joanna
    Younes, Anas
    Zelenetz, Andrew D.
    Zhang, Zhigang
    Moskowitz, Craig H.
    [J]. BLOOD, 2016, 128 (11) : 1458 - 1464
12345